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Dear editor, 
In the RESORCE trial 1, Bruix and colleagues reported the data of regorafenib in patients with 
hepatocellular carcinoma (HCC) who progressed after sorafenib treatment. Regorafenib improved 
overall survival (OS) with an hazard ratio (HR) of 0.63 (95% CI 0.50-0.79) . In the subgroup 
analysis, the HR for OS in HBV-positive patients was 0.58 (95% CI 0.41-0.82 p=0.0009) with 
respect to 0.79 (95% CI 0.49-1.26 p=0.1583) observed in HCV-positive patients. Similar data were 
observed for progression free survival (0.39 vs 0.59 respectively) and time to progression (0.38 vs 
0.57 respectively). Different results were observed in relation to first line treatment with sorefenib. 
In the subgroup analysis of the SHARP study2, HR relative to OS was 0.76 in HBV-positive 
patients (95% CI 0.38-1.50 p= not significant), with respect to 0.50 (95% CI 0.32-0.77) observed in 
HVC-positive patients, and the data were similar for time to progression (HR 1.03 and 0.43 for 
HBV-positive and HCV-positive patients, respectively). Similar data were obtained in HBV 
positive- HCC patients by the subgroup analysis of the phase III study of Sorafenib Asia–Pacific 
trial, where the HR for OS was 0.74 (0.51-1.06, not significant) respect to patients with other 
etiology, for which the HR was 0.57 (0.29-1.33). These results seem to suggest a different efficacy 
of sorafenib and regorafenib in HCV or HBV – positive HCC. HCV-mediated hepatocarcinogenesis 
seems to be strongly mediated by type I and III IFN, which induce a plethora of IFN stimulated 
genes, together with the ability of HCV core to modulate intracellular pathways and cellular 
metabolism, through the induction of kinases phosphorylation4. In this setting the multikinase 
inhibitor sorafenib seems to be more efficacious. On the other hand, HBV-positive HCC seem to be 
characterized by a IL-6 dependent inflammatory process, together with different genomic 
perturbations due to viral DNA integration4. Regorafenib, an anti-VEGFR2-TIE2 and multikinase 
inhibitor, seems to be more efficacious in this type of HCC, in which may be there is a more 
intensive involvement of the angiogenic process. Differences in the mechanisms of action of the 
two drugs , together with the diversity in tumor microenvironment characteristics on the basis of 
HBV or HCV infection could explain the different antitumor profile.  
In conclusion, these observations lead to hypothesize a different treatment strategy based on tumor 
etiology. Future studies should be made to evaluate if the use of first line regorafenib in HBV-
positive HCC patients may be the best strategy for improving the outcome of these patients. 
Another interesting point that has not been taken in consideration in the subgroup analysis of both 
RESORCE and SHARP trials is the effect of the drugs in patients with metabolic syndrome.  
Specific studies aimed to understand the efficacy of drugs in relation to HCC etiology are warranted 
to clarify this aspect. 
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